Shanghai Shyndec Pharmaceutical Co Ltd Financial Flexibility Index
Shanghai Shyndec Pharmaceutical Co Ltd financial flexibility index. Shanghai Shyndec Pharmaceutical Co Ltd (600420) has a Financial Flexibility Index of 0.15x as of September 2025. Free cash flow of CN¥553.14 Million (operating CF CN¥486.04 Million minus capex CN¥67.11 Million) represents 0% of total liabilities (CN¥3.63 Billion). See Shanghai Shyndec Pharmaceutical Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Shanghai Shyndec Pharmaceutical Co Ltd (2004–2024)
Financial flexibility index of Shanghai Shyndec Pharmaceutical Co Ltd from 2004 to 2024. Historical Financial Flexibility Index trend for Shanghai Shyndec Pharmaceutical Co Ltd across 21 annual periods. Check how high is Shanghai Shyndec Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Shanghai Shyndec Pharmaceutical Co Ltd Financial Flexibility Index by Year (2004–2024)
Shanghai Shyndec Pharmaceutical Co Ltd financial flexibility index by year from 2004 to 2024. Year-by-year free cash flow to debt coverage for Shanghai Shyndec Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 600420 cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.53x | CN¥2.48 Billion | CN¥2.26 Billion | CN¥4.63 Billion | ▲ +28.9% |
| 2023 | 0.41x | CN¥2.08 Billion | CN¥1.72 Billion | CN¥5.01 Billion | ▼ -2.0% |
| 2022 | 0.42x | CN¥3.16 Billion | CN¥2.86 Billion | CN¥7.48 Billion | ▲ +67.2% |
| 2021 | 0.25x | CN¥2.20 Billion | CN¥1.68 Billion | CN¥8.70 Billion | ▲ +10.1% |
| 2020 | 0.23x | CN¥1.94 Billion | CN¥1.56 Billion | CN¥8.43 Billion | ▲ +15.8% |
| 2019 | 0.20x | CN¥1.67 Billion | CN¥1.27 Billion | CN¥8.44 Billion | ▼ -23.1% |
| 2018 | 0.26x | CN¥2.07 Billion | CN¥1.67 Billion | CN¥8.02 Billion | ▼ -21.9% |
| 2017 | 0.33x | CN¥2.48 Billion | CN¥2.31 Billion | CN¥7.52 Billion | ▲ +146.9% |
| 2016 | 0.13x | CN¥1.08 Billion | CN¥838.58 Million | CN¥8.08 Billion | ▼ -26.8% |
| 2015 | 0.18x | CN¥461.17 Million | CN¥226.65 Million | CN¥2.53 Billion | ▼ -36.0% |
| 2014 | 0.29x | CN¥689.05 Million | CN¥258.51 Million | CN¥2.42 Billion | ▼ -27.9% |
| 2013 | 0.40x | CN¥720.12 Million | CN¥207.50 Million | CN¥1.82 Billion | ▼ -15.6% |
| 2012 | 0.47x | CN¥598.94 Million | CN¥193.41 Million | CN¥1.28 Billion | ▼ -3.5% |
| 2011 | 0.49x | CN¥264.52 Million | CN¥136.12 Million | CN¥544.70 Million | ▼ -46.6% |
| 2010 | 0.91x | CN¥271.12 Million | CN¥115.11 Million | CN¥298.05 Million | ▲ +51.4% |
| 2009 | 0.60x | CN¥128.73 Million | CN¥97.43 Million | CN¥214.24 Million | ▲ +37.1% |
| 2008 | 0.44x | CN¥71.60 Million | CN¥58.04 Million | CN¥163.41 Million | ▼ -55.1% |
| 2007 | 0.98x | CN¥116.76 Million | CN¥82.31 Million | CN¥119.57 Million | ▼ -38.0% |
| 2006 | 1.57x | CN¥135.59 Million | CN¥73.60 Million | CN¥86.15 Million | ▲ +29.6% |
| 2005 | 1.21x | CN¥129.55 Million | CN¥57.90 Million | CN¥106.67 Million | ▲ +175.1% |
| 2004 | 0.44x | CN¥32.81 Million | CN¥17.02 Million | CN¥74.32 Million | — |